Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction

Circulation

Volumn 109, Issue 18, 2004, Pages 2186-2190

  Shimpo, Masahisa ^a   Morrow, David A ^a   Weinberg, Ellen O ^a   Sabatine, Marc S ^a   Murphy, Sabina A ^a   Antman, Elliott M ^a   Lee, Richard T ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Interleukins; Myocardial infarction; Prognosis; Receptors

Indexed keywords

ABCIXIMAB; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CREATINE KINASE MB; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; INTERLEUKIN 1 RECEPTOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ST2; PROTEIN ST2; TENECTEPLASE; TROPONIN I; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD CLOT LYSIS; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; DIAGNOSTIC VALUE; DISEASE MARKER; ELECTROCARDIOGRAM; FEMALE; HUMAN; INFLAMMATION; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OPEN STUDY; PATHOPHYSIOLOGY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL;

AGED; ANTIBODIES, MONOCLONAL; ANTICOAGULANTS; CLINICAL TRIALS; COMORBIDITY; DRUG THERAPY, COMBINATION; ENOXAPARIN; FEMALE; FIBRINOLYTIC AGENTS; HEART FAILURE, CONGESTIVE; HOSPITAL MORTALITY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INCIDENCE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; RECEPTORS, CELL SURFACE; RISK FACTORS; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TREATMENT OUTCOME;

EID: 2442621252     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000127958.21003.5A     Document Type: Article

References (18)

1. Sims JE. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol. 2002;14:117-122.
2. O'Neill L. The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence. Biochem Soc Trans. 2000;28:557-563.
3. Tominaga S. A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett. 1989;258:301-304.
4. Townsend MJ, Fallon PG, Matthews DJ, et al. T1/ST2-deficient mice demonstrate the importance of T1/ST2 in developing primary T helper cell type 2 responses. J Exp Med. 2000;191:1069-1076.
5. Walzl G, Matthews S, Kendall S, et al. Inhibition of T1/ST2 during respiratory syncytial virus infection prevents T helper cell type 2 (Th2)- but not Th1-driven immunopathology. J Exp Med. 2001;193:785-792.
6. Weinberg EO, Shimpo M, De Keulenaer GW, et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106:2961-2966.
7. Weinberg EO, Shimpo M, Hurwitz S, et al. Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation. 2003;107:721-726.
8. Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the Thrombolysis In Myocardial Infarction (TIMI) 14 trial: the TIMI 14 Investigators. Circulation. 1999;99:2720-2732.
9. Antman EM, Gibson CM, de Lemos JA, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14: the Thrombolysis in Myocardial Infarction (TIMI) 14 Investigators. Eur Heart J. 2000;21:1944-1953.
10. Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation. 2002;105:1642-1649.
11. Morrow DA, Rifai N, Antman EM, et al. C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy: Thrombolysis in Myocardial Infarction. J Am Coll Cardiol. 1998;31:1460-1465.
12. Morrow DA, Rifai N, Tanasijevic MJ, et al. Clinical efficacy of three assays for cardiac troponin I for risk stratification in acute coronary syndromes: a Thrombolysis In Myocardial Infarction (TIMI) 11B Substudy. Clin Chem. 2000;46:453-460.
13. Yasue H, Yoshimura M, Sumida H, et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90:195-203.
14. Morrow DA, Antman EM, Charlesworth A, et al. TIMI risk score for ST-elevation myocardial infarction: a convenient, bedside, clinical score for risk assessment at presentation: an intravenous nPA for treatment of infarcting myocardium early II trial substudy. Circulation. 2000;102: 2031-2037.
15. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014-1021.
16. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med. 1996;335:1342-1349.
17. Oshikawa K, Kuroiwa K, Tago K, et al. Elevated soluble ST2 protein levels in sera of patients with asthma with an acute exacerbation. Am J Respir Crit Care Med. 2001;164:277-281.
18. Kuroiwa K, Arai T, Okazaki H, et al. Identification of human ST2 protein in the sera of patients with autoimmune diseases. Biochem Biophys Res Commun. 2001;284:1104-1108.